Limited-edition collaboration and fresh dividend decision draw attention to Dillard's stock
Dillard's (DDS) has rolled out the Amanda Jones Vaughan x Antonio Melani limited-edition collection across its stores and website, and has also affirmed a regular cash dividend, giving investors fresh company specific developments to watch.
See our latest analysis for Dillard's.
Despite a recent 30 day share price return of a 10.25% decline and a 90 day share price return of an 18.14% decline from a last close of US$598.17, Dillard's has still produced a very large 5 year total shareholder return of around 7x. This suggests long term holders have been rewarded even as shorter term momentum has cooled.
If this kind of fashion collaboration has you thinking about what else might be setting up for the next big move, take a look at our 20 top founder-led companies as a starting point for ideas beyond retail.
With Dillard's trading around US$598.17 after strong multi year returns but a recent pullback and a value score of just 2, investors now face a key question: is there still mispricing here, or is the market already assuming future growth?
Most Popular Narrative: 3.7% Overvalued
Compared to the latest close of $598.17, the most followed narrative from Vestra pegs Dillard's fair value at $576.90, leaving only a small gap for investors to debate.
Dillard's (DDS) is currently operating as a masterclass in capital discipline within the retail sector, trading at $611.60 as of the March 3, 2026, close. The stock has been a battleground for investors lately, as it works to digest its Q4 2025 earnings report released on February 24.
Curious what sits behind that fair value line in the sand? Vestra leans heavily on future earnings power, margin resilience and a premium P/E multiple to get there. The full narrative joins those pieces together into one clear pricing story.
Result: Fair Value of $576.90 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this story could change quickly if comparable store sales remain under pressure, or if higher operating expenses squeeze that 40.8% retail gross margin.
Find out about the key risks to this Dillard's narrative.
Another View: Earnings Power vs Price Tag
While the Vestra narrative leans on a future P/E of 18x and a fair value of $576.90, our model paints a tougher picture. On our DCF model, Dillard's fair value sits at $440.10, which would leave the current $598.17 price looking expensive.
That gap between earnings based fair value and the SWS DCF model raises a simple question for you: do you trust the cash flow math or the earnings multiple more for a business with this profile?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
If this mix of upside and risk still feels finely balanced, consider reviewing the numbers yourself and forming your own view, starting with 2 key rewards and 1 important warning sign.
Looking for more investment ideas?
You have already done the work on Dillard's, so do not stop there when a broader set of opportunities could be one screener away from your radar.
- Target resilient compounding potential by scanning our 48 high quality undervalued stocks, which pairs quality fundamentals with prices that still look reasonable on the numbers.
- Prioritise sleep at night holdings using our 68 resilient stocks with low risk scores, focused on companies with steadier risk profiles and fewer red flags.
- Get ahead of the crowd by running through our screener containing 23 high quality undiscovered gems before these quieter names move onto everyone else's watchlists.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com